Exclusive Summary

• • Strong efficacy: The monotherapy efficacy can break the immune tolerance of CHB patients. Combo regimen with the preventive HBsAg vaccine can induce the production of HBsAg-specific antibodies in mouse models, significantly reducing the HBsAg antigen. • Innovation: It fused with type I IFNα and CD4+ T cell helper peptide to stimulate antiviral immune responses, enhancing the vaccine's immune efficacy by hundreds to thousands of times. Potent and durable HBV-specific immune responses can be achieved even in the absence of adjuvants.
• • Differentiation with viral vector vaccines: Fusion protein vaccines allow for repeated dosing